Comparing two treatments for advanced liver cancer
A Multicenter, Randomized, Open-label Phase II Study of ZG005 Combined With Bevacizumab Versus Sintilimab Combined With Bevacizumab for First-line Treatment of Advanced Hepatocellular Carcinoma
PHASE2 · Suzhou Zelgen Biopharmaceuticals Co.,Ltd · NCT06558227
This study is testing which combination of two treatments works better for people with advanced liver cancer.
Quick facts
| Phase | PHASE2 |
|---|---|
| Study type | Interventional |
| Enrollment | 90 (estimated) |
| Ages | 18 Years to 75 Years |
| Sex | All |
| Sponsor | Suzhou Zelgen Biopharmaceuticals Co.,Ltd (industry) |
| Drugs / interventions | Bevacizumab, Sintilimab |
| Locations | 1 site (Chengdu, Sichuan) |
| Trial ID | NCT06558227 on ClinicalTrials.gov |
What this trial studies
This clinical trial is a randomized, open-label, multicenter phase II study that evaluates the efficacy and safety of ZG005 combined with Bevacizumab versus Sintilimab combined with Bevacizumab in patients with advanced hepatocellular carcinoma. The trial aims to determine which combination is more effective as a first-line treatment. Participants will be monitored for their response to treatment and any potential side effects. The study is designed to provide insights into the best therapeutic options for this challenging condition.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18-75 with advanced hepatocellular carcinoma and an ECOG performance status of 0 or 1.
Not a fit: Patients who are not suitable for participation as determined by the investigator will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved treatment options for patients with advanced hepatocellular carcinoma.
How similar studies have performed: Other studies have explored similar combination therapies in hepatocellular carcinoma, showing promising results, but this specific combination is being evaluated for the first time.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Fully understand the study and voluntarily sign the informed consent form. * 18-75 years of age; * Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1； * Life expectancy ≥ 12 weeks. Exclusion Criteria: * Patients were deemed unsuitable for participating in the study by the investigator for any reasons.
Where this trial is running
Chengdu, Sichuan
- West China Hospital of Sichuan University — Chengdu, Sichuan, China (RECRUITING)
Study contacts
- Study coordinator: Bo Liu
- Email: liub@zelgen.com
- Phone: +86-021-5838-2983
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Hepatocellular Carcinoma